Efficacy of Octreotide-lar versus Surgery in Treating Acromegaly
There are several treatment options for patients with acromegaly. A recent study looked at two treatments in particular: octreotide-lar (Oct-LAR) and surgery. The researchers wanted to see how well the treatments control IFG-1 levels, GH levels, and tumor volumes; they also examined the side effects of the treatments.
This was a randomized, prospective study involving 22 patients. The results were published in the November 2011 issue of Clinical Endocrinology (Oxford) in an article called “Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly.”
The patients were consecutively randomized to either the Oct-LAR or surgery group. The following were obtained at baseline:
- serum IGF-1 level
- GH level
- tumor volume
These were comparable in both groups.
At 3 months and 6 months, there weren’t any significant differences between the groups in terms of IGF-1 levels and GH levels. However, at 12 months, the pre-glucose GH level was lower in the surgery group.
In the Oct-LAR group, tumor volume reduction was: 26% (3 months), 30% (6 months), and 31% (12 months).
In the surgery group, tumor volume reduction was: 64% (3 months), 74% (6 months), and 79% (12 months).
In conclusion, the researchers say that surgery seems to be slightly more effective than Oct-LAR for patients with acromegaly who have non-invasive tumors. Also, it should be noted that Oct-LAR is associated with more side effects, including cholelithiasis, and it is more costly than surgery.